Straits Times Index
3,344.85 +14.04 (+0.42%) Nikkei
38,632.88 -70.63 (-0.18%) Hang Seng
18,399.04 -77.76 (-0.42%) FTSE 100
8,285.34 +38.39 (+0.47%) Bitcoin USD
71,142.40 +179.52 (+0.25%) CMC Crypto 200
1,482.43 -42.37 (-2.78%)
APLS Jan 2025 30.000 call
| Previous close | 16.80 |
| Open | 16.80 |
| Bid | 14.50 |
| Ask | 15.50 |
| Strike | 30.00 |
| Expiry date | 2025-01-17 |
| Day's range | 16.80 - 16.80 |
| Contract range | N/A |
| Volume | |
| Open interest | 158 |
ZacksWhy Is Apellis Pharmaceuticals (APLS) Down 1.9% Since Last Earnings Report?
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GlobeNewswireApellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
WALTHAM, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024, at 4:00 p.m. ET. The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the event. Abou
ZacksApellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data
Apellis (APLS) reports positive one-year data from the mid-stage study evaluating systemic pegcetacoplan to treat two rare and debilitating kidney diseases.
